$SINOMAB BIO-B(03681)$ view or

$SINOMAB BIO-B(03681)$ view order details.@Trade Feed Decoder

03681

06-17 10:57

HKSINOMAB BIO-B

Side	Price \| Filled	Realized P&L
Buy Open	1.95 5,100	-- Closed

SINOMAB BIO-B

Trade Feed: Who is your favorite trader?

Come to the Trade Feed Topic to find more trading opportunities! Also, please feel free to recommend and introduce fellow Tigers to the "hidden gem traders" that you've discovered!

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Trade Feed Decoder
06-17
Trade Feed Decoder
Analysis of SINOMAB BIO-B (03681) trade: The +3.08% gain on this biotech stock suggests a focused short-term strategy given the sector's inherent volatility. The entry at HK$1.95 aligns with typical small-cap biotech pricing, requiring careful liquidity consideration. While the profit demonstrates effective timing, biotech investments often hinge on clinical trial outcomes or regulatory events that weren't disclosed here. The trade's success appears driven by acute risk/reward assessment rather than fundamental shifts, as no major company announcements coincide with the trade date. This execution highlights the importance of strict exit protocols in speculative sectors. However, the ultra-low stock price warrants attention to position sizing to manage volatility risks inherent in developmental-stage biopharma plays.

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":446906018423040,"tweetId":"446906018423040","gmtCreate":1750129231268,"gmtModify":1750667157473,"author":{"id":4194581874692312,"idStr":"4194581874692312","authorId":4194581874692312,"authorIdStr":"4194581874692312","name":"彈啫啫","avatar":"https://community-static.tradeup.com/news/0d64eed19139b44d505c10681ec6e355","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":119,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":109,"starInvestorOrderShareNum":527,"userFollowInvestorFlag":false,"orderNotificationFlag":false,"ror":51.48,"showRor":true,"investmentPhilosophy":"投資就係低買，高賣\n買中就贏，買錯就輸\n聽日一定會好天既","winRationPercentage":86.192469,"tradeVolumeEst":0},"themes":[{"themeId":"4e1ab37448a24dd39b7882426fc6fd27","categoryId":"ab3d937a5fd848c08008411a9be702b5","name":"Trade Feed: Who is your favorite trader?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":4e1ab37448a24dd39b7882426fc6fd27}&rnconfig={\"headerBarHidden\": true}","description":"Come to the Trade Feed Topic to find more trading opportunities! Also, please feel free to recommend and introduce fellow Tigers to the \"hidden gem traders\" that you've discovered!","image":"https://community-static.tradeup.com/news/e496e574dd744490c7b4f7959f83f5a4"}],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/03681\">$SINOMAB BIO-B(03681)$&nbsp;</a>view order details.<a href=\"https://ttm.financial/U/10000000000011061\">@Trade Feed Decoder</a></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/03681\">$SINOMAB BIO-B(03681)$&nbsp;</a>view order details.<a href=\"https://ttm.financial/U/10000000000011061\">@Trade Feed Decoder</a></body></html>","text":"$SINOMAB BIO-B(03681)$ view order details.@Trade Feed Decoder","highlighted":1,"essential":1,"paper":1,"likeSize":51,"commentSize":1,"repostSize":28,"favoriteSize":0,"link":"https://ttm.financial/post/446906018423040","repostId":0,"isVote":1,"tweetType":1,"viewCount":2536,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["03681"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":true,"orderData":{"uuid":"4194581874692312","orderId":"39482796196253696","kind":"TRADE","symbol":"03681","secType":"STK","symbolHtmlTag":"<a href=\"https://ttm.financial/S/03681\">$SINOMAB BIO-B(03681)$&nbsp;</a>","symbolHtmlTagHref":"https://ttm.financial/S/03681","symbolName":"SINOMAB BIO-B","market":"HK","action":"BUY","currency":"HKD","symbolLogo":"","showFilledQuantity":true,"nameCN":"SINOMAB BIO-B","orderType":"LMT","filledQuantityFinal":5100,"avgFillPrice":1.95,"createTime":1750129047,"filledQuantity":"5100","filledQuantityScale":"0","openFlag":true,"side":"DEBIT","contractMajorDescription":"SINOMAB BIO-B","contractExtraDescription":"03681","legs":[],"completedFlag":true,"orderPnl":{"openRealizedPnlPercent":0.1763},"quickOrderFlag":false},"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["订单分享帖","未分享订单分享帖"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":34,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":446993215439016,"commentId":"446993215439016","gmtCreate":1750136136558,"gmtModify":1750136546677,"authorId":10000000000011060,"author":{"id":10000000000011060,"idStr":"10000000000011061","authorId":10000000000011060,"name":"Trade Feed Decoder","avatar":"https://community-static.tradeup.com/news/4dc8fec78bad5acffbf563bdbc6bc8ed","vip":4,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":446906018423040,"objectIdStr":"446906018423040","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Analysis of SINOMAB BIO-B (03681) trade: The +3.08% gain on this biotech stock suggests a focused short-term strategy given the sector's inherent volatility. The entry at HK$1.95 aligns with typical small-cap biotech pricing, requiring careful liquidity consideration. While the profit demonstrates effective timing, biotech investments often hinge on clinical trial outcomes or regulatory events that weren't disclosed here. The trade's success appears driven by acute risk/reward assessment rather than fundamental shifts, as no major company announcements coincide with the trade date. This execution highlights the importance of strict exit protocols in speculative sectors. However, the ultra-low stock price warrants attention to position sizing to manage volatility risks inherent in developmental-stage biopharma plays.","text":"Analysis of SINOMAB BIO-B (03681) trade: The +3.08% gain on this biotech stock suggests a focused short-term strategy given the sector's inherent volatility. The entry at HK$1.95 aligns with typical small-cap biotech pricing, requiring careful liquidity consideration. While the profit demonstrates effective timing, biotech investments often hinge on clinical trial outcomes or regulatory events that weren't disclosed here. The trade's success appears driven by acute risk/reward assessment rather than fundamental shifts, as no major company announcements coincide with the trade date. This execution highlights the importance of strict exit protocols in speculative sectors. However, the ultra-low stock price warrants attention to position sizing to manage volatility risks inherent in developmental-stage biopharma plays.","html":"Analysis of SINOMAB BIO-B (03681) trade: The +3.08% gain on this biotech stock suggests a focused short-term strategy given the sector's inherent volatility. The entry at HK$1.95 aligns with typical small-cap biotech pricing, requiring careful liquidity consideration. While the profit demonstrates effective timing, biotech investments often hinge on clinical trial outcomes or regulatory events that weren't disclosed here. The trade's success appears driven by acute risk/reward assessment rather than fundamental shifts, as no major company announcements coincide with the trade date. This execution highlights the importance of strict exit protocols in speculative sectors. However, the ultra-low stock price warrants attention to position sizing to manage volatility risks inherent in developmental-stage biopharma plays.","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"hot","coins":0,"score":0,"disclaimerFlag":true,"disclaimerType":1,"specialCommentTag":"AI_ANALYSE"}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/446906018423040"}